Onivyde resources?

Here are reliable resources you can use to learn about Onivyde (liposomal irinotecan) and its use in pancreatic cancer. I’ve grouped them by purpose so you can pick what you need.

Regulatory/official information
- FDA Onivyde prescribing information (label): official dosing, indications, warnings, and adverse events (search “Onivyde liposomal irinotecan FDA label”).
- DailyMed Onivyde entry: consumer-friendly and regulatory-facing drug labeling information.
- EMA/European product information (if you’re looking outside the US): the European regulatory page and patient information for Onivyde in Europe.

Clinical trial evidence
- NAPOLI-1 trial publication: pivotal phase 3 trial showing the benefit of liposomal irinotecan plus 5-FU/LV after gemcitabine failure in metastatic pancreatic cancer. Look for the trial report in major journals (Lancet/Lancet Oncology era). This is the foundational evidence behind the approval.
- ClinicalTrials.gov: search for “Onivyde” or “liposomal irinotecan” to view trial details, results, and related studies.

Guidelines and practice recommendations
- NCCN Guidelines for Pancreatic Adenocarcinoma: current recommendations for sequencing and when Onivyde + 5-FU/LV is considered after gemcitabine therapy.
- ESMO (and other major society) guidelines for pancreatic cancer: guidance on systemic therapy options, including liposomal irinotecan-based regimens.

Drug information databases and pharmacology
- PubChem: Onivyde entry (chemical information, descriptors, related compounds).
- DrugBank: Onivyde entry (mechanism, pharmacology, and related data).

Patient- and clinician-facing information
- Manufacturer/clinical education pages: Onivyde product pages from the sponsor (for clinicians and patients) with dosing overview, safety, and administration notes.
- National Cancer Institute (NCI) resources on pancreatic cancer and treatment options; patient-friendly information on chemotherapy regimens including irinotecan-containing therapies.
- AACR/ASCO/NCI patient guides and fact sheets on pancreatic cancer and its treatments.

Practical pointers
- For dosing and safety specifics, use the official prescribing information (FDA label) as the primary reference.
- If you’re evaluating this for a specific patient, cross-check the latest NCCN/ESMO guidelines for your region and the current FDA labeling, as recommendations and approved indications can evolve.
- If you’d like, I can pull current direct links to each resource (FDA label, DailyMed page, the NAPOLI-1 trial paper, NCCN guideline page, etc.) tailored to your region (US vs. Europe). Just tell me which resources you want and your location.

Would you like me to fetch and compile direct URLs to the most up-to-date official pages and key publications? If so, tell me whether you’re in the US or another country and whether you need clinician-focused or patient-focused materials.